Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Macular Pigmentation Clear all
Completed No phase listed Observational Results available

Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)

NCT01272076
View directory record Official record
Conditions
Age Related Macular Degeneration, Geographic Atrophy
Interventions
Not listed
Lead sponsor
Carl Zeiss Meditec, Inc.
Industry
Eligibility
50 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Oakland, California • Jackson, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60

NCT00121589
View directory record Official record
Conditions
Macular Degeneration
Interventions
Lutein
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Antioxidants on Human Macular Pigments

NCT00718653
View directory record Official record
Conditions
Eye Health
Interventions
Lutein, Lutein plus green tea extract
Dietary Supplement
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2009 · Synced Sep 11, 2026, 2:56 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Pistachios and Neural Macular Pigment

NCT05283941
View directory record Official record
Conditions
Macular Degeneration, Retinal Degeneration, Retinal Diseases, Eye Diseases
Interventions
Pistachio Group
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
40 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Early Phase 1 Interventional Results available

Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation

NCT03478865
View directory record Official record
Conditions
AMD
Interventions
Vitamin A palmitate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia

NCT01205035
View directory record Official record
Conditions
Retinal Diseases, Telangiectasis
Interventions
ranibizumab 2.0mg
Drug
Lead sponsor
Eye Center of Northern Colorado, P.C.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 11, 2026, 2:56 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Macular Pigment Measurements in Eye & Other Tissues

NCT03022773
View directory record Official record
Conditions
Macular Pigmentation, Skin Pigment
Interventions
Carotenoid measurements
Other
Lead sponsor
University of Utah
Other
Eligibility
7 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 11, 2026, 2:56 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD

NCT02590692
View directory record Official record
Conditions
Dry Macular Degeneration, Geographic Atrophy
Interventions
CPCB-RPE1
Biological
Lead sponsor
Regenerative Patch Technologies, LLC
Industry
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Sep 11, 2026, 2:56 AM EDT
Completed No phase listed Observational

Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography

NCT01272063
View directory record Official record
Conditions
Drusen Stage Macular Degeneration
Interventions
Not listed
Lead sponsor
Carl Zeiss Meditec, Inc.
Industry
Eligibility
50 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Oakland, California • San Francisco, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 11, 2026, 2:56 AM EDT
Completed No phase listed Observational

The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel)

NCT01354093
View directory record Official record
Conditions
Idiopathic Juxtafoveal Telangiectasia
Interventions
zeaxanthin
Drug
Lead sponsor
Paul S. Bernstein
Other
Eligibility
50 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 11, 2026, 2:56 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of C.001 in Retinal Degeneration

NCT07594236
View directory record Official record
Conditions
Geographic Atrophy, Stargardt Disease, RPE-mediated Maculopathy, Age Related Macular Degeneration
Interventions
Injection
Biological
Lead sponsor
Cellio Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Beverly Hills, California • Palo Alto, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Gojiberry Intake (Lycium Barbarium) on Macular Function

NCT03983525
View directory record Official record
Conditions
Macular Pigment Optical Density
Interventions
Goji berry, Lutein + zeaxanthin supplementation
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
45 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration

NCT00306488
View directory record Official record
Conditions
Geographic Atrophy, Age-Related Macular Degeneration, AMD
Interventions
OT-551 antioxidant eye drop
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)

NCT00931489
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab (Lucentis(R))
Drug
Lead sponsor
Lawrence S. Morse, MD
Other
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 11, 2026, 2:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

NCT02286089
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
OpRegen
Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
3
States / cities
San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 11, 2026, 2:56 AM EDT
Terminated Phase 1 Interventional

iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)

NCT01334255
View directory record Official record
Conditions
Pigment Epithelial Detachment
Interventions
iSONEP (sonepcizumab/LT1009)
Drug
Lead sponsor
Lpath, Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Winter Haven, Florida • West Mifflin, Pennsylvania • West Columbia, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Sep 11, 2026, 2:56 AM EDT
Completed No phase listed Observational

Repeatability and Reproducibility of Cirrus HD-OCT Macular Retinal Pigment Epithelium Elevation

NCT01890174
View directory record Official record
Conditions
Dry AMD With Macular Drusen
Interventions
Not listed
Lead sponsor
Carl Zeiss Meditec, Inc.
Industry
Eligibility
50 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2013 · Synced Sep 11, 2026, 2:56 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Macular Pigment and Visual Performance in Glaucoma Patients

NCT03959592
View directory record Official record
Conditions
Glaucoma
Interventions
Lutein, zeaxanthin and mesozeaxanthin, Placebo
Drug · Other
Lead sponsor
Felipe Medeiros, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 2, 2023 · Synced Sep 11, 2026, 2:56 AM EDT
Terminated Phase 2 Interventional

HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration

NCT01189019
View directory record Official record
Conditions
Wet Macular Degeneration, Macular Degeneration, Retinal Pigment Epithelial Detachment
Interventions
ranibizumab
Drug
Lead sponsor
Anne Fung MD
Other
Eligibility
50 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 11, 2026, 2:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

NCT04339764
View directory record Official record
Conditions
Dry Age-Related Macular Degeneration, Geographic Atrophy
Interventions
iPSC-derived RPE/PLGA transplantation
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Not applicable Interventional

Diabetes Visual Function Supplement Study

NCT01646047
View directory record Official record
Conditions
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
Interventions
multi-component nutritional supplement capsules, multi-component dietary supplement
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Sep 11, 2026, 2:56 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Phase 2Phase 3 Interventional

Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments

NCT00590694
View directory record Official record
Conditions
Age-related Macular Degeneration, Pigment Epithelial Detachment, Neovascular Macular Degeneration, Wet Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
Pacific Eye Associates
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Sep 11, 2026, 2:56 AM EDT
Completed Not applicable Interventional

The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism

NCT02200263
View directory record Official record
Conditions
Ocular Albinism (OA), Oculocutaneous Albinism (OCA)
Interventions
Lutein plus Zeaxanthin, Placebo
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Sep 11, 2026, 2:56 AM EDT